WO2019132787A1 - Improved metered-dose nasal spray formulation of beclomethasone dipropionate - Google Patents
Improved metered-dose nasal spray formulation of beclomethasone dipropionate Download PDFInfo
- Publication number
- WO2019132787A1 WO2019132787A1 PCT/TR2017/000152 TR2017000152W WO2019132787A1 WO 2019132787 A1 WO2019132787 A1 WO 2019132787A1 TR 2017000152 W TR2017000152 W TR 2017000152W WO 2019132787 A1 WO2019132787 A1 WO 2019132787A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beclomethasone dipropionate
- range
- nasal
- per
- film
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title claims abstract description 25
- 229950000210 beclometasone dipropionate Drugs 0.000 title claims abstract description 20
- 238000009472 formulation Methods 0.000 title claims abstract description 13
- 229940014206 metered dose nasal spray Drugs 0.000 title claims abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 10
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 6
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 6
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 6
- OFNNKPAERNWEDD-UHFFFAOYSA-L disodium;2,3-dihydroxypropyl phosphate;hydrate Chemical compound O.[Na+].[Na+].OCC(O)COP([O-])([O-])=O OFNNKPAERNWEDD-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 description 20
- 230000032258 transport Effects 0.000 description 9
- 206010039085 Rhinitis allergic Diseases 0.000 description 8
- 201000010105 allergic rhinitis Diseases 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000007922 nasal spray Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 229940097496 nasal spray Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001331781 Aspergillus brasiliensis Species 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010039094 Rhinitis perennial Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 2
- -1 polyol salts Chemical class 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
Definitions
- the present invention relates to improved nasal spray formulation of beclomethasone dipropionate comprising; a film forming polymer, an antibacterial agent; a viscosity increasing agent having antibacterial properties with an advantageous effect on the nasal mucosa in case of allergic rhinitis and provided in the form of metered-dose nasal spray formulation.
- U.S. 5,843,881 A relates to a spray composition that contains alcohol, a polymer and an alcohol- masking perfume additive. The compositions are applied to the skin, the hair or the mucosa.
- Epithelial host defense molecules include small peptides that lyse bacteria. Lysozyme targets glycosidic bonds in the peptidoglycan cell wall of bacteria, typically leading to an enzymatic lysis, and is highly effective against many common upper airway gram-positive bacteria, such as streptococci.
- Allergic rhinitis, nonallergic rhinitis, and chronic rhinosinusitis are described as inflammatory upper airway diseases with high prevalence and variations in their characteristics. The diseases are affected by each other, by lower airway diseases, by the composition of inhaled air, infections, the sensitization profile, and many genetic and lifestylerelated factors. Allergic rhinitis is an IgE-mediated symptomatic inflammation with a prevalence of 10-20 % in worldwide population. In the route of nasal passages, as a common rhinitides, allergic rhinitis (hay fever) causes to the nasal mucosa to swelling and lead to palpitations and respiratory disorders while changing its pH range to more alkaline environment, mostly greater than pH value of 6.5.
- Lysozyme breaks some of the bonds between the peptidoglycans in the cell wall of a bacterium.
- Lysozyme is an antibacterial enzyme found in body secretions, including saliva, mucus, tears, and human milk where acts as a part of body defence system against invading microbes. Lysozyme levels were decreased significantly in patients with perennial allergic rhinitis with recurrent sinusitis and reduced lysozyme concentrations can be critical factor which predispose the airways of patients with perennial allergic rhinitis.
- Nasal mucosa has been known to carry amoeba and consequently could represent an important natural reservoir for Bacterial strains and act as a Trojan horse allowing bacteria to access the respiratory tract.
- Bacteria appears to result from various efflux pumps that efficiently remove antibiotics/or corticosteroid molecules from the cell, decreased contact of the drug molecule with the bacterial cell surface due to Bacterial ability to form biofilms, and changes in the cell epithelium to reduce the permeability of the membrane to the drug molecules like antibiotics and corticosteroid molecules.
- Beclomethasone dipropionate is an anti-inflammatory corticosteroid having the chemical name 9-chloro-11b,17,21-trihydroxy-l6b-methylpregna-1,4-diene-3,20-doine17,21- dipropionate, beclomethasone dipropionate indicated in the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis having structure already defined in Patent No 3,312,590 which to use of anti-inflammatory compounds in topical preparations for the local treatment of inflammations.
- Beclomethasone dipropionate is the active component of present dosage form, Nasal spray, in the invention having an anti-inflammatory steroid indication.
- the compositions of the prior art needs improvements in terms of antibacterial activity during allergic rhinitis between where give sufficient prevention of drug molecules from said bacterial biofilms leading to decrease the penetration of drug molecules in the application area.
- the invention provides a metered-dose nasal spray formulation comprising beclomethasone dipropionate, wherein the formulation is in the following antibacterial film forming agents content;
- glycerol phosphate disodium salt hydrate in range of 0.05 - 5 mg per ml
- hydroxyethylcellulose in the range of 0.01 - 1 mg per ml
- micronized beclomethasone dipropionate d90 ⁇ 5 ⁇
- micronized beclomethasone dipropionate d90 ⁇ 5 ⁇
- the composition comprises from 0.01 to 1 mg, preferably from 0.05 to 0.5 mg, more preferably from 0.1 to 0.3 mg of film forming polymer per 1 ml of nasal film composition.
- the film forming polymer is selected from the group of polymers which are versatile, organosoluble, and thermoplastic polymers, more preferably polymers derived from cellulose, ethylcellulose base done repeating anhydroglucose units.
- the composition comprises from 0.05 to 5 mg, preferably from 0.1 to 3 mg, more preferably from 0.5 to 2 mg of viscosity increasing agent per 1 ml of nasal film composition.
- the viscosity increasing agent is selected from polyol salts having cabability to adjust film forming efficiency with varying of its concentration in the prefered composition, preferably Glycerophosphate salts, more preferably Glycerol phosphate disodium salt hydrate.
- the composition comprises from 0,1 to 10 mg, preferably from 0,2 to 5 mg, more preferably from 1 to 3 mg of antibacterial agent per 1 ml of nasal film composition.
- the antibacterial agent is selected from the group of Alkali metal salts of sorbic acid considering of considered harmless to the motility of ciliated cellsin mucosa, more preferably potassium salt of sorbic acid, as Potassium sorbate.
- the composition is a nasal spray, having capability of film forming characteristics.
- composition of the invention is notably for the improvement of antibacterial capabilities and pathologies of the upper airways.
- the invention also provides a dispenser, preferably equipped with a spray pump, containing the nasal film composition of the invention.
- the invention also relates to the potassium sorbate as an antibacterial agent, owing to its antibacterial characteristics in nasal film structure be able to prevent possible bacterial growth in alkali pH values in the case of allergic rhinitis during patient use.
- the compositions of the invention therefore, provides harmless, imperceptible, homogenous film on the nasal mucosa which protects it from possible bacterial growth between daily application of the doses.
- An object of the present invention is to provide simulating the behaviour of Lysozyme enzyme which loses its activity in the symptoms of rhinitis due to the change of pH from acidic to alkali values, greater than pH 6.5.
- the invention also allows for improved anti-bacterial efficiency of the actuated product onto the mucosal surface without any damage to mucosal epitelhium.
- a dose would typically be one actuation into each nostril, and generally not more than 4 doses totally per day.
- the typical content of a dose is about 100 ⁇ L.
- Table 1 represents the concentration of components in order to obtain Nasal Film composition
- the invention further provides advantages as will be apparent from the description.
- the film-forming activity of the present invention provides sufficient time to drug molecules to penetrate into the nasal mucosal epithelium surface with forming uniform and elastic polymer film layer including antibacterial preservative, as Potassium sorbate, which prevents possible bacterial growth in alkaline pH values during allergic rhinitis with showing good stability in cell tolerance test performed with Calu-3 monolayers.
- antibacterial preservative as Potassium sorbate
- AET Antimicrobial Effectiveness Test
- TEER values were constantly higher than 300 W-cm 2 over the whole period of the transport studies.
- the adhesion during the 30 minute incubation phase was low but after 270 minutes no active ingredient be detected in the donor.
- Test formulations, nasal film, had suitable results in tolerance test with good stability of the active ingredient and yielded similar absorbtion behaviour with spray formulations.
- test compounds were diluted with transport medium (HBSS, pH 7.4 to appropriate yield concentrations) (see Table 2).
- concentration of Beclomethasone transport solution was adjusted to the concentration of Beclomethasone dipropionate in the transport solution for test items A to C to ensure that the same theoretical concentration API was applied on the cell mon-olayers (see Table ).
- the amount API in the donor decreased tremendously from ca. 700 ⁇ g ⁇ mL -1 to 100 ⁇ g ⁇ mL -1 for Beclomethasone dipropionate in apical to basolateral transport direction and to ca. 50 ⁇ g ⁇ mL -1 for the basolateral to apical transport direction.
- This decrease may be caused by the adhesion of the lipophilic substance to plastic material of the Transwell system and possibly by an uptake of API in the cells. This adhesion process occurs normally within 30 minutes.
- no further decrease of the donor concentration occurs. Indicating the adhesion resp., uptake was complete.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates a metered-dose nasal spray formulation comprising beclomethasone dipropionate, wherein the formulation is in the following antibacterial film forming agents content; potassium sorbate in range of 0.1 - 10 mg per ml, glycerol phosphate disodium salt hydrate in range of 0.05 - 5 mg per ml, and hydroxyethylcellulose in the range of 0.01 - 1 mg per ml, characterized by comprising micronized beclomethasone dipropionate (d90≤5µ) in the range of 0.05 to 0.1 % as weight per volume basis.
Description
IMPROVED METERED-DOSE NASAL SPRAY FORMULATION OF BECLOMETHASONE DIPROPIONATE
FIELD OF THE INVENTION
The present invention relates to improved nasal spray formulation of beclomethasone dipropionate comprising; a film forming polymer, an antibacterial agent; a viscosity increasing agent having antibacterial properties with an advantageous effect on the nasal mucosa in case of allergic rhinitis and provided in the form of metered-dose nasal spray formulation.
TECHNICAL BACKGROUND
Nasal sprays known in the art where the examples of EP 0 216 917 B 1 refers to a therapeutic preparation for nasal administration that contains a thickening agent as methylcellulose. U.S. 5,843,881 A relates to a spray composition that contains alcohol, a polymer and an alcohol- masking perfume additive. The compositions are applied to the skin, the hair or the mucosa.
Both mucosal and glandular epithelial secrete a large array of molecules that are known to kill or neutralize microorganisms. The risk of colonization or infection by microorganisms might leads to chronic airway inflammation. Epithelial host defense molecules include small peptides that lyse bacteria. Lysozyme targets glycosidic bonds in the peptidoglycan cell wall of bacteria, typically leading to an enzymatic lysis, and is highly effective against many common upper airway gram-positive bacteria, such as streptococci.
Allergic rhinitis, nonallergic rhinitis, and chronic rhinosinusitis are described as inflammatory upper airway diseases with high prevalence and variations in their characteristics. The diseases are affected by each other, by lower airway diseases, by the composition of inhaled air, infections, the sensitization profile, and many genetic and lifestylerelated factors. Allergic rhinitis is an IgE-mediated symptomatic inflammation with a prevalence of 10-20 % in worldwide population.
In the route of nasal passages, as a common rhinitides, allergic rhinitis (hay fever) causes to the nasal mucosa to swelling and lead to palpitations and respiratory disorders while changing its pH range to more alkaline environment, mostly greater than pH value of 6.5.
Regarding with the change in pH range in the case of allergic rhinitis, the effect of pH on the thermal stability of lysozyme enzyme became important. It is known from the literature that the maximum thermal stability of the Lysozym enzyme at pH 5.0 is due to minimum aggregation, and when the pH is further increased from 5.0 to 7.0, increase in aggregation decreases the thermal stability at pH 6.0 and 7.0 which leads to decrease in thermal stability of the enzyme causes inactivation of the ability to hydrolyzes glycosidic bonds between the monosaccharide units of bacterial glycoprotein cell wall, represented in Figure 1.
Figure 1. Lysozyme breaks some of the bonds between the peptidoglycans in the cell wall of a bacterium.
Lysozyme is an antibacterial enzyme found in body secretions, including saliva, mucus, tears, and human milk where acts as a part of body defence system against invading microbes. Lysozyme levels were decreased significantly in patients with perennial allergic rhinitis with recurrent sinusitis and reduced lysozyme concentrations can be critical factor which predispose the airways of patients with perennial allergic rhinitis.
Nasal mucosa has been known to carry amoeba and consequently could represent an important natural reservoir for Bacterial strains and act as a Trojan horse allowing bacteria to access the respiratory tract. Bacteria appears to result from various efflux pumps that efficiently remove antibiotics/or corticosteroid molecules from the cell, decreased contact of the drug molecule with the bacterial cell surface due to Bacterial ability to form biofilms, and
changes in the cell epithelium to reduce the permeability of the membrane to the drug molecules like antibiotics and corticosteroid molecules.
Beclomethasone dipropionate is an anti-inflammatory corticosteroid having the chemical name 9-chloro-11b,17,21-trihydroxy-l6b-methylpregna-1,4-diene-3,20-doine17,21- dipropionate, beclomethasone dipropionate indicated in the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis having structure already defined in Patent No 3,312,590 which to use of anti-inflammatory compounds in topical preparations for the local treatment of inflammations.
Beclomethasone dipropionate is the active component of present dosage form, Nasal spray, in the invention having an anti-inflammatory steroid indication. The compositions of the prior art needs improvements in terms of antibacterial activity during allergic rhinitis between where give sufficient prevention of drug molecules from said bacterial biofilms leading to decrease the penetration of drug molecules in the application area.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides a metered-dose nasal spray formulation comprising beclomethasone dipropionate, wherein the formulation is in the following antibacterial film forming agents content;
a) potassium sorbate in range of 0.1 - 10 mg per ml,
b) glycerol phosphate disodium salt hydrate in range of 0.05 - 5 mg per ml, c) hydroxyethylcellulose in the range of 0.01 - 1 mg per ml,
characterized by comprising micronized beclomethasone dipropionate (d90≤5μ) in the range of 0.05 to 0.1 % as weight per volume basis.
According to one embodiment, the composition comprises from 0.01 to 1 mg, preferably from 0.05 to 0.5 mg, more preferably from 0.1 to 0.3 mg of film forming polymer per 1 ml of nasal film composition.
According to one embodiment, the film forming polymer is selected from the group of polymers which are versatile, organosoluble, and thermoplastic polymers, more preferably polymers derived from cellulose, ethylcellulose base done repeating anhydroglucose units.
According to one embodiment, the composition comprises from 0.05 to 5 mg, preferably from 0.1 to 3 mg, more preferably from 0.5 to 2 mg of viscosity increasing agent per 1 ml of nasal film composition.
According to one embodiment, the viscosity increasing agent is selected from polyol salts having cabability to adjust film forming efficiency with varying of its concentration in the prefered composition, preferably Glycerophosphate salts, more preferably Glycerol phosphate disodium salt hydrate.
According to one embodiment, the composition comprises from 0,1 to 10 mg, preferably from 0,2 to 5 mg, more preferably from 1 to 3 mg of antibacterial agent per 1 ml of nasal film composition.
According to one embodiment, the antibacterial agent is selected from the group of Alkali metal salts of sorbic acid considering of considered harmless to the motility of ciliated cellsin mucosa, more preferably potassium salt of sorbic acid, as Potassium sorbate.
According to one embodiment, the composition is a nasal spray, having capability of film forming characteristics.
The composition of the invention is notably for the improvement of antibacterial capabilities and pathologies of the upper airways.
The invention also provides a dispenser, preferably equipped with a spray pump, containing the nasal film composition of the invention.
The invention also relates to the potassium sorbate as an antibacterial agent, owing to its antibacterial characteristics in nasal film structure be able to prevent possible bacterial growth in alkali pH values in the case of allergic rhinitis during patient use.
The compositions of the invention therefore, provides harmless, imperceptible, homogenous film on the nasal mucosa which protects it from possible bacterial growth between daily application of the doses.
An object of the present invention is to provide simulating the behaviour of Lysozyme enzyme which loses its activity in the symptoms of rhinitis due to the change of pH from acidic to alkali values, greater than pH 6.5. The invention also allows for improved anti-bacterial efficiency of the actuated product onto the mucosal surface without any damage to mucosal epitelhium. A dose would typically be one actuation into each nostril, and generally not more than 4 doses totally per day. The typical content of a dose is about 100μL. Table 1 represents the concentration of components in order to obtain Nasal Film composition,
Table 1. Stable Nasal Film Composition comprising Beclomethasone dipropionate
The invention further provides advantages as will be apparent from the description.
The film-forming activity of the present invention provides sufficient time to drug molecules to penetrate into the nasal mucosal epithelium surface with forming uniform and elastic polymer film layer including antibacterial preservative, as Potassium sorbate, which prevents
possible bacterial growth in alkaline pH values during allergic rhinitis with showing good stability in cell tolerance test performed with Calu-3 monolayers.
Antimicrobial Effectiveness Test (AET) were performed for nasal film suspension as represented in Figure 2, which justifies the requirements of antimicrobial effectiveness of the final Nasal film product conposition according to current European Pharmacopea monograph.
Figure 2. Antimicrobial Effectiveness Test (AET) for Nasal Film Suspension Composition The study focused on the Microbicidal effect of nasal film on indigenous microbes regarding with the intrinsic antimicrobial properties of nasal film against indigenous microbes with following method,
Method
Four isolates were used: Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans and Aspergillus brasiliensis. Method were tested in order to evaluate the effectiveness of antimicrobial Nasal Film at 48 hours (test performed over 48 hours due to slow growth of Aspergillus brasiliensis and Candida albicans strains) following inoculation, bacteria were collected from film surfaces and enumerated. LoglO reductions were calculated by
subtracting time point log 10 count on control and test surfaces from the initial inoculum. Figure 3 represents the antimicrobial effectiveness results for Nasal Film Surface.
Figure 3. The Antimicrobial Effectiveness Results for Nasal Film Surface, over 48 hours
Although initially all samples contained nearly 1x106 CFU/mL, For Nasal Film samples, the CFU value gradually decreased during incubation and nearly diminished of Staphylococcus aureus and Pseudomonas aeruginosa at 24 hours, and at 48 hours for Candida albicans and Aspergillus brasiliensis.
Regarding with the determination of film forming behaviour of the Nasal Film composition, said film composition defined in the invention, Oscillatory tests were performed yielded results of higher storage modulus G' obtained rather than loss modulus G” which defines that formed Nasal Film showed chracteristics of viscoelastic solid in Figure 4.
Figure 4. Oscillatory Test Results for having ethylcellulose amounts of 0.05 mg/ml; 0.1 mg/ml and 0.2 mg/ml for Samples, Blue, Red and Blue, respectively The present study also investigate the local tolerance and the in-vitro nasal permeation of Beclomethasone dipropionate in nasal spray, nasal film formulations. For this purpose monolayers of the human bronchial cell line Calu-3 were used. Calu-3 cells represent a suitable model to study respiratory drug delivery in vitro in order to quantify the drug’s absorption the cumulative transport from the apical to the basolateral side of the cell monolayers. TEER (Trans epithelial electrical resistance) values for Calu-3 monolayers were determined. TEER values were constantly higher than 300 W-cm2 over the whole period of the transport studies. The adhesion during the 30 minute incubation phase was low but after 270 minutes no active ingredient be detected in the donor. Test formulations, nasal film, had
suitable results in tolerance test with good stability of the active ingredient and yielded similar absorbtion behaviour with spray formulations.
The permeation experiments were performed with HBSS + 1 % MeOH + 0.25 % Tween 80 as acceptor medium with n=6 for each tested API.
The test compounds were diluted with transport medium (HBSS, pH 7.4 to appropriate yield concentrations) (see Table 2). The concentration of Beclomethasone transport solution was adjusted to the concentration of Beclomethasone dipropionate in the transport solution for test items A to C to ensure that the same theoretical concentration API was applied on the cell mon-olayers (see Table ).
Table 2. Preparation of the stock solutions of Beclomethasone dipropionate (pure API) for the permeation experiment
For all APIs a suspension was obtained which were mixed well and applied as suspension to the cells. In the following table the theoretical concentrations of the suspensions are given together with the measured concentrations of the supernatant of each transport solution. Therefore the suspension was diluted with ACN/H2075:25 (v/v; %). The concentrations were recalculated us-ing the dilution factor.Test item B and C refers Nasal Spray and Nasal Film compositions, respectively.
Table 3. Summary of in vitro permeability testing Beclomethasone dipropionate across Calu- 3 cell mono-layers.
Table 4. Summary of in vitro permeability testing Beclomethasone dipropionate across Calu- 3 cell mono-layers.
Figure 6. TEER values [%] of negative control HBSS, positive control HBSS + 0.1 % SDS, Rinoclenil in three concentrations and Test Item B and Test Item C with 500 μg mL-1, 0 min (after addition of the test substance), and after 60, 120 and 240 min. Depicted are the mean values from three replicates and the standard deviation.
Claims
1. A metered-dose nasal spray formulation comprising beclomethasone dipropionate, wherein the formulation is in the following antibacterial film forming agents content;
d) potassium sorbate in range of 0.1 - 10 mg per ml,
e) glycerol phosphate disodium salt hydrate in range of 0.05 - 5 mg per ml, f) hydroxyethylcellulose in the range of 0.01 - 1 mg per ml,
characterized by comprising micronized beclomethasone dipropionate (d90≤5μ) in the range of 0.05 to 0.1 % as weight per volume basis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2017/000152 WO2019132787A1 (en) | 2017-12-29 | 2017-12-29 | Improved metered-dose nasal spray formulation of beclomethasone dipropionate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2017/000152 WO2019132787A1 (en) | 2017-12-29 | 2017-12-29 | Improved metered-dose nasal spray formulation of beclomethasone dipropionate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019132787A1 true WO2019132787A1 (en) | 2019-07-04 |
Family
ID=67067935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2017/000152 WO2019132787A1 (en) | 2017-12-29 | 2017-12-29 | Improved metered-dose nasal spray formulation of beclomethasone dipropionate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019132787A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844902A (en) * | 1987-02-17 | 1989-07-04 | Bayer Aktiengesellschaft | Topically applicable formulations of gyrase inhibitors in combination with corticosteroids |
| WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
-
2017
- 2017-12-29 WO PCT/TR2017/000152 patent/WO2019132787A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844902A (en) * | 1987-02-17 | 1989-07-04 | Bayer Aktiengesellschaft | Topically applicable formulations of gyrase inhibitors in combination with corticosteroids |
| WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1137685C (en) | Non-irritation, non-sensitizing non-ototoxic otic antibacterial compositions | |
| JP5726774B2 (en) | Topical ophthalmic suspension of loteprednol etabonate and tobramycin | |
| CN102448496B (en) | Medicine composition having iodine and steroid and application to treatment of rhinitis | |
| US11576973B2 (en) | Pharmaceutical formulations that form gel in situ | |
| JP2018531292A6 (en) | Pharmaceutical formulations that form gels in situ | |
| CN110869023B (en) | In situ gel forming pharmaceutical composition and its use in sinus disease | |
| JP6200108B2 (en) | Ophthalmic composition for the treatment of eye infections | |
| CN113662915B (en) | An ophthalmic pharmaceutical composition | |
| EP3422851B1 (en) | Antimicrobial compositions containing polyquaternium | |
| ES2860098T3 (en) | Composition for nasal application | |
| CN101987109B (en) | Ophthalmic composition containing povidone iodine and cyclodextrin included glucocorticoid | |
| EP3993788B1 (en) | Nasal spray for use for the treatment of infections with sars-cov-2 | |
| WO2019132787A1 (en) | Improved metered-dose nasal spray formulation of beclomethasone dipropionate | |
| CN108096272A (en) | Antifungal infection product for children skin and preparation method thereof | |
| CN113694093B (en) | Antibacterial and anti-inflammatory quillajasaponins gel and preparation method thereof | |
| CN116251118B (en) | Artificial saliva, artificial saliva bursting beads, preparation method thereof, and application thereof in xerostomia | |
| US20230149333A1 (en) | Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections | |
| JP2012523450A (en) | Medicinal cream produced using flamicetin sulfate cream and chitosan and method for producing the same | |
| US11944684B2 (en) | Composition for treating and/or preventing fungal infections | |
| US20080248135A1 (en) | Combination Therapy for Otitis with Antiseptic and pH Adjustment | |
| Maslii et al. | Testing of antimicrobial activity of preservatives for dental gels development | |
| TW202206069A (en) | Ophthalmic pharmaceutical composition comprising atropine | |
| WO2018203327A1 (en) | Composition containing phenethyl alcohol for treatment of candida infection | |
| EP2908911A1 (en) | Compositions comprising a silver salt of sucrose octasulfate and a potassium salt of sucrose octasulfate for protection of mucosal epithelia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17935899 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17935899 Country of ref document: EP Kind code of ref document: A1 |